Abstract 305P
Background
The prognosis in patients with breast cancer with isolated locoregional recurrence (ILRR) without simultaneous distant metastases after immediate breast reconstruction (IBR) remains unknown. We aimed to investigate the prognosis in this patient population.
Methods
This multi-institutional retrospective observational study evaluated 3,295 patients with primary breast cancer who underwent IBR at 12 Japanese medical facilities between January 1, 2008 and December 31, 2016. The outcome measures were the prognostic factors for ILRR after IBR, 5-year distant metastasis-free survival (DMFS), and 5-year overall survival (OS).
Results
Mastectomy or skin-sparing mastectomy was performed in 3,295 patients. ILRR occurred in 70 patients, and the median observation period from ILRR diagnosis was 39.3 months. Of the 70 patients, 9 (12.9%) had axillary lymph node recurrence (ALNR) at the time of ILRR diagnosis. The 5-year DMFS after ILRR was 92.4%. Patients with ILRR who had ALNR had a significantly worse DMFS than that had by those without ALNR (P = 0.005).The 5-year OS after ILRR was 91.2%. Patients with ILRR who had ALNR had a significantly worse OS than that had by those without ALNR (P = 0.005).The relationship between DMFS and clinicopathological factors was analyzed using the Cox proportional hazards model. Univariate analysis revealed significant associations of pN at primary surgery (P = 0.041) and ALNR at ILRR (HR: 9.960, 95% CI: 1.400–70.862, P = 0.022) with DMFS. However, ALNR was the only independent prognostic factor for DMFS in the multivariate analysis (P = 0.041). Univariate analysis revealed significant associations of post-mastectomy radiation therapy (PMRT) at primary surgery (P = 0.023) and ALNR at ILRR (P = 0.043) with OS. In multivariate analysis, both PMRT (P = 0.010) and ALNR (P = 0.028) were independent prognostic factors for OS.
Conclusions
Although patients with breast cancer who have ILRR after IBR have a favorable prognosis overall, ALNR at the diagnosis of ILRR may be a poor prognostic factor. Our results may contribute to developing strategies to predict prognosis in patients with breast cancer who develop ILRR after IBR.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
291P - Multi-center investigation of a detection model utilizing cfDNA for early-stage breast cancer screening
Presenter: Chao Ni
Session: Poster session 14
292P - Real-world evidence on risk of recurrence (ROR) in patients (pts) with node-negative (N0) and node-positive HR+/HER2– early breast cancer (EBC) from US electronic health records (EHR)
Presenter: Komal Jhaveri
Session: Poster session 14
293P - Ultra-sensitive ctDNA detection and monitoring in early breast cancer using PhasED-Seq
Presenter: Luc Cabel
Session: Poster session 14
294P - Survival outcomes according to tumor-infiltrating lymphocytes and 21-gene recurrence score in ER+HER2- breast cancer
Presenter: Sung Gwe Ahn
Session: Poster session 14
295P - Long-term clinical outcomes and treatment strategy considerations by ER expression level in breast cancer
Presenter: Yumi Wanifuchi-Endo
Session: Poster session 14
296P - Investigating survival by breast cancer molecular subtype in Australia: A population-based study
Presenter: Larissa Vaz-Goncalves
Session: Poster session 14
297P - Real-world data on prognostication of early stage breast cancer patients using CanAssist Breast- first immunohistochemistry based prognostic test developed and validated on Asians
Presenter: Vashista Maniar
Session: Poster session 14
Resources:
Abstract
298P - Enhancing prognostic accuracy for breast adenoid cystic carcinoma using machine learning models
Presenter: Sakhr Alshwayyat
Session: Poster session 14
Resources:
Abstract
299P - Characterization and clinical outcomes of low hormonal receptor positive / HER2 negative early breast cancer
Presenter: Jitnarong Karnmanee
Session: Poster session 14
300P - Gene expression landscape of the long-term tamoxifen resistance in premenopausal ER+ breast cancer patients in the STO-5 controlled randomized clinical trial with >20-year follow-up
Presenter: Julia Tutzauer
Session: Poster session 14